In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive ...
In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
For years, the clinical trial industry has been sold an appealing idea: participant adherence is largely a problem that can ...
In this Q&A, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how clinical ...
A multi-stakeholder tabletop exercise evaluated SSDC integration into pragmatic trials, emphasizing fit-for-purpose safety ...
Lastly, a broader view of clinical outcomes and operational insights is a cornerstone to product value translation. Gathering ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results